Biocryst Pharmaceuticals vs Legend Biotech
Legend Biotech is the larger business, with $1.03bn of revenue in fiscal 2025 against $875m for Biocryst Pharmaceuticals (1.2 times as much). Biocryst Pharmaceuticals grew faster (94.1% against 64.0%). Biocryst Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 30.2% against -28.8%.
| Latest fiscal year | Biocryst PharmaceuticalsBCRX, 2025 | Legend BiotechLEGN, 2025 |
|---|---|---|
| Revenue | $875m | $1.03bn |
| Revenue growth | 94.1% | 64.0% |
| Net income | $264m | −$297m |
| Operating margin | 39.0% | -13.3% |
| Net margin | 30.2% | -28.8% |
| Return on equity | — | -29.1% |
| Free cash flow | $345m | −$129m |
| Cash | $89.7m | $902m |
| Total debt | $0 | $319m |
| Debt to equity | — | 31.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 435 | — |
| Market value | $2.19bn | $3.97bn |
| Price vs our value range | Below our value range | — |
| Moat score | 46 (Moderate) | — |
| Insider trades, 12 months | 0 buys, 10 sales | 0 buys, 5 sales |